FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212836670> ?p ?o ?g. }

• W4212836670 endingPage "1710" @default.
• W4212836670 startingPage "1697" @default.
• W4212836670 abstract "Antifungal prophylaxis in patients at high risk for invasive fungal infections (IFIs), such as those with acute myeloid leukemia or myelodysplastic syndromes, continues to be underused in Asia, despite the fact that it reduces IFI-related death and increases IFI-free survival. We characterized the pharmacokinetics (PK) and safety of the intravenous (IV) formulation of posaconazole in adult Asian participants at high risk for IFI. Participants received posaconazole IV 300 mg twice on day 1, posaconazole IV 300 mg once daily on days 2–10, and posaconazole IV 300 mg once daily or oral suspension 200 mg 3 times daily for up to 18 days for a maximum of 28 days. There were two PK sampling groups: intensive and sparse. Sparse trough PK sampling was collected from all participants on days 3, 6, 10, 15, 22, and 28/end of treatment. The intensive PK group had additional sampling performed over 24 h on day 10. Primary end points were steady state average concentration (Cavg,ss) and percentage of participants with Cavg,ss ≥ 500 ng/mL. Safety was assessed up to day 30/end of treatment. Seventy participants with acute myelogenous leukemia were enrolled, 30 in the intensive PK group and 40 in the sparse PK group; 57 participants completed the study, 26 in the intensive PK group and 31 in the sparse PK group. On day 10, arithmetic mean Cavg,ss was 2986 ng/mL [coefficient of variation (%CV), 36%; range, 1409–5930 ng/mL]; 100% of participants in the intensive PK group (n/N = 27/27) had Cavg,ss ≥ 500 ng/mL. Arithmetic mean (%CV) Cmin was 2474 (50.4%) and 2466 ng/mL (42.4%) in the intensive and sparse PK groups on day 10, respectively. Safety was similar to that of previous posaconazole formulations. In Asian participants at high risk for IFIs, IV posaconazole achieved the target exposure associated with efficacy that was previously established for supporting global registration of posaconazole for IV administration and was generally well tolerated. ClinicalTrials.gov, NCT03336502." @default.
• W4212836670 created "2022-02-24" @default.
• W4212836670 creator A5006739024 @default.
• W4212836670 creator A5010445699 @default.
• W4212836670 creator A5016508145 @default.
• W4212836670 creator A5027220663 @default.
• W4212836670 creator A5030968272 @default.
• W4212836670 creator A5036634103 @default.
• W4212836670 creator A5053916580 @default.
• W4212836670 creator A5070756038 @default.
• W4212836670 creator A5072208411 @default.
• W4212836670 creator A5080338192 @default.
• W4212836670 creator A5083897514 @default.
• W4212836670 date "2022-02-15" @default.
• W4212836670 modified "2023-10-18" @default.
• W4212836670 title "Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections" @default.
• W4212836670 cites W1736726786 @default.
• W4212836670 cites W1982405193 @default.
• W4212836670 cites W1988385266 @default.
• W4212836670 cites W1989345554 @default.
• W4212836670 cites W2014611012 @default.
• W4212836670 cites W2030566485 @default.
• W4212836670 cites W2056158943 @default.
• W4212836670 cites W2070395634 @default.
• W4212836670 cites W2106243271 @default.
• W4212836670 cites W2114061161 @default.
• W4212836670 cites W2117813373 @default.
• W4212836670 cites W2139126851 @default.
• W4212836670 cites W2162626697 @default.
• W4212836670 cites W2164830432 @default.
• W4212836670 cites W2166734004 @default.
• W4212836670 cites W2175975424 @default.
• W4212836670 cites W2418920851 @default.
• W4212836670 cites W2598656679 @default.
• W4212836670 cites W2742352005 @default.
• W4212836670 cites W2761141716 @default.
• W4212836670 cites W2799470600 @default.
• W4212836670 cites W2805704277 @default.
• W4212836670 cites W2969608688 @default.
• W4212836670 cites W2982356680 @default.
• W4212836670 cites W3017007448 @default.
• W4212836670 cites W3187645783 @default.
• W4212836670 doi "https://doi.org/10.1007/s12325-021-02012-1" @default.
• W4212836670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35167031" @default.
• W4212836670 hasPublicationYear "2022" @default.
• W4212836670 type Work @default.
• W4212836670 citedByCount "1" @default.
• W4212836670 countsByYear W42128366702022 @default.
• W4212836670 crossrefType "journal-article" @default.
• W4212836670 hasAuthorship W4212836670A5006739024 @default.
• W4212836670 hasAuthorship W4212836670A5010445699 @default.
• W4212836670 hasAuthorship W4212836670A5016508145 @default.
• W4212836670 hasAuthorship W4212836670A5027220663 @default.
• W4212836670 hasAuthorship W4212836670A5030968272 @default.
• W4212836670 hasAuthorship W4212836670A5036634103 @default.
• W4212836670 hasAuthorship W4212836670A5053916580 @default.
• W4212836670 hasAuthorship W4212836670A5070756038 @default.
• W4212836670 hasAuthorship W4212836670A5072208411 @default.
• W4212836670 hasAuthorship W4212836670A5080338192 @default.
• W4212836670 hasAuthorship W4212836670A5083897514 @default.
• W4212836670 hasBestOaLocation W42128366701 @default.
• W4212836670 hasConcept C112705442 @default.
• W4212836670 hasConcept C126322002 @default.
• W4212836670 hasConcept C16005928 @default.
• W4212836670 hasConcept C177713679 @default.
• W4212836670 hasConcept C2778566413 @default.
• W4212836670 hasConcept C2779548794 @default.
• W4212836670 hasConcept C2780007613 @default.
• W4212836670 hasConcept C2780690907 @default.
• W4212836670 hasConcept C2780817109 @default.
• W4212836670 hasConcept C2987404301 @default.
• W4212836670 hasConcept C71924100 @default.
• W4212836670 hasConcept C90924648 @default.
• W4212836670 hasConceptScore W4212836670C112705442 @default.
• W4212836670 hasConceptScore W4212836670C126322002 @default.
• W4212836670 hasConceptScore W4212836670C16005928 @default.
• W4212836670 hasConceptScore W4212836670C177713679 @default.
• W4212836670 hasConceptScore W4212836670C2778566413 @default.
• W4212836670 hasConceptScore W4212836670C2779548794 @default.
• W4212836670 hasConceptScore W4212836670C2780007613 @default.
• W4212836670 hasConceptScore W4212836670C2780690907 @default.
• W4212836670 hasConceptScore W4212836670C2780817109 @default.
• W4212836670 hasConceptScore W4212836670C2987404301 @default.
• W4212836670 hasConceptScore W4212836670C71924100 @default.
• W4212836670 hasConceptScore W4212836670C90924648 @default.
• W4212836670 hasIssue "4" @default.
• W4212836670 hasLocation W42128366701 @default.
• W4212836670 hasLocation W42128366702 @default.
• W4212836670 hasLocation W42128366703 @default.
• W4212836670 hasOpenAccess W4212836670 @default.
• W4212836670 hasPrimaryLocation W42128366701 @default.
• W4212836670 hasRelatedWork W1984228185 @default.
• W4212836670 hasRelatedWork W2049323988 @default.
• W4212836670 hasRelatedWork W2144098567 @default.
• W4212836670 hasRelatedWork W2162626697 @default.
• W4212836670 hasRelatedWork W2194258360 @default.
• W4212836670 hasRelatedWork W2327741408 @default.
• W4212836670 hasRelatedWork W2609926236 @default.

• next